PROF:NASDAQ, Profound Medical Corp.
PROF stock overview
Profound Medical Corp. (PROF:NASDAQ) closed at $5.56 on October 23, 2026,
down 3.47% on the day.
The stock trades 37.9% below its 52-week high of $8.95
and 15.8% above its 52-week low of $4.80.
Over the past year, it gained 1.1%.
Profound Medical Corp. is part of the Health Care sector.
Key figures
- Price
- $5.56
- Day change
- -3.47%
- Volume
- 135,858
- Average volume
- 196,518
- Market cap
- 203M+
- 52-week range
- $4.80 – $8.95
- 50-day average
- $6.34
- 200-day average
- $6.75
Price action over the past year
In 252 trading sessions since October 23, 2025, PROF closed higher on 115 days (46%).
Its best day was October 8, 2026 (+21.65%) and its worst was March 6, 2026 (-29.11%).
The stock moved 10% or more in a single session 7 times.
It opened at least 5% above the previous day's high 1 time.
Recent signals
PROF news
-
Oct 22, 2026:
Emmy-Award Winning Television Host Montel Williams to Join Next 'Let's Huddle' Webinar
-
Oct 22, 2026:
Emmy-Award Winning Television Host Montel Williams to Join Next ‘Let's Huddle' Webinar
-
Oct 18, 2026:
3 Canadian AI Healthcare Stocks With Market Caps Up To CA$312 Million
-
Oct 14, 2026:
Does Profound Medical (PROF) Have the Potential to Rally 58.77% as Wall Street Analysts Expect?
-
Oct 14, 2026:
TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity
-
Oct 11, 2026:
Profound Medical And 2 Canadian AI Healthcare Stocks To Watch
-
Oct 9, 2026:
Profound Medical and Telix Pharmaceuticals Partner to Advance Prostate Cancer Imaging and Treatment Education
-
Oct 9, 2026:
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
About Profound Medical Corp.
Profound Medical Corp is a medical technology company. It provides incision-free therapies that combine real-time Magnetic Resonance (MR) imaging, thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue. The company develops a treatment to ablate the prostate gland in prostate cancer patients.
Similar stocks
Find more stocks like PROF with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.